IN2014DN07509A - - Google Patents

Info

Publication number
IN2014DN07509A
IN2014DN07509A IN7509DEN2014A IN2014DN07509A IN 2014DN07509 A IN2014DN07509 A IN 2014DN07509A IN 7509DEN2014 A IN7509DEN2014 A IN 7509DEN2014A IN 2014DN07509 A IN2014DN07509 A IN 2014DN07509A
Authority
IN
India
Prior art keywords
independently
optionally substituted
therapy
halogen
compounds
Prior art date
Application number
Other languages
English (en)
Inventor
Stephen Joseph Shuttleworth
Franck Alexandre Silva
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Publication of IN2014DN07509A publication Critical patent/IN2014DN07509A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN7509DEN2014 2012-03-08 2013-03-08 IN2014DN07509A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1204125.7A GB201204125D0 (en) 2012-03-08 2012-03-08 Compounds
PCT/GB2013/050583 WO2013132270A1 (en) 2012-03-08 2013-03-08 Phosphoinositide 3-kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN07509A true IN2014DN07509A (de) 2015-04-24

Family

ID=46026238

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7509DEN2014 IN2014DN07509A (de) 2012-03-08 2013-03-08

Country Status (6)

Country Link
US (2) US9663487B2 (de)
EP (1) EP2822943B1 (de)
CN (1) CN104254532A (de)
GB (1) GB201204125D0 (de)
IN (1) IN2014DN07509A (de)
WO (1) WO2013132270A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2467387B1 (de) 2009-08-20 2015-01-07 Karus Therapeutics Limited Trizyklische heterocyclische verbindungen als phosphoinositide 3-kinase hemmer
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
NZ707366A (en) 2012-11-07 2018-11-30 Karus Therapeutics Ltd Novel histone deacetylase inhibitors and their use in therapy
EA035391B1 (ru) 2012-11-08 2020-06-05 Ризен Фармасьютикалз Са Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
WO2014181137A1 (en) 2013-05-10 2014-11-13 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
UY38144A (es) 2018-03-12 2019-10-31 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1296975A1 (de) * 2000-06-30 2003-04-02 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinone und ihre anwendung als protein kinase inhibitoren
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
JP4703183B2 (ja) 2002-07-15 2011-06-15 シンフォニー エボルーション， インク． 受容体型キナーゼモジュレーターおよびその使用方法
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2005217320B2 (en) 2004-02-26 2011-07-21 Aska Pharmaceuticals Co., Ltd. Pyrimidine derivative
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
ZA200710379B (en) * 2005-05-20 2009-05-27 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
EP1979353A2 (de) * 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Kondensierte heterobizyklische kinaseinhibitoren
BRPI0710866A2 (pt) 2006-04-26 2012-08-14 Hoffmann La Roche compostos farmacÊuticos
AR060632A1 (es) 2006-04-26 2008-07-02 Genentech Inc Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso
CN101605797A (zh) 2006-11-13 2009-12-16 伊莱利利公司 治疗炎症疾病和癌症的噻吩并嘧啶酮
AU2008210455A1 (en) * 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
CN101663276A (zh) * 2007-01-31 2010-03-03 沃泰克斯药物股份有限公司 用作激酶抑制剂的2-氨基吡啶衍生物
EP2139332A4 (de) 2007-03-28 2010-04-21 Merck Sharp & Dohme Substituierte pyrido[2,3-d]pyrimidinderivate als cannabinoid-1-rezeptormodulatoren
JP2010529031A (ja) 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
JP2011529932A (ja) 2008-08-05 2011-12-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ナフチリジン及び医薬としてのその使用
WO2010037765A2 (en) 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
EP2459543B1 (de) 2009-07-29 2017-08-30 Karus Therapeutics Limited Benzo[e][1,3]oxazin-4-on-derivate als phosphoinositid 3-kinase-hemmer
EP2467387B1 (de) 2009-08-20 2015-01-07 Karus Therapeutics Limited Trizyklische heterocyclische verbindungen als phosphoinositide 3-kinase hemmer
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
RS54653B1 (en) 2011-07-27 2016-08-31 Astrazeneca Ab 2- (2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
JP6430390B2 (ja) 2012-11-20 2018-11-28 ジェネンテック， インコーポレイテッド Ｔ７９０ｍを含むｅｇｆｒ変異体の阻害剤としてのアミノピリミジン化合物
WO2014181137A1 (en) 2013-05-10 2014-11-13 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
EP3052494B1 (de) 2013-06-28 2018-12-26 H. Hoffnabb-La Roche Ag Azaindazolverbindungen als inhibitoren von t790m-haltigen egfr-mutanten
EP3054953B1 (de) 2013-10-10 2020-07-01 Acetylon Pharmaceuticals, Inc. Hdac-hemmer in kombination mit pi3k-hemmern, zur behandlung von nicht-hodgkin-lymphomen
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
US20180072699A1 (en) 2018-03-15
CN104254532A (zh) 2014-12-31
US9663487B2 (en) 2017-05-30
WO2013132270A1 (en) 2013-09-12
GB201204125D0 (en) 2012-04-25
US10035785B2 (en) 2018-07-31
US20150080395A1 (en) 2015-03-19
EP2822943B1 (de) 2018-10-03
EP2822943A1 (de) 2015-01-14

Similar Documents

Publication Publication Date Title
IN2014DN07509A (de)
MX2016006336A (es) Compuestos pirazolopirimidina.
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
TN2012000401A1 (en) Heterocyclic compound
NZ705705A (en) Ret inhibitor
PH12014501719A1 (en) Pyridone derivatives
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
MX344025B (es) Inhibidores de proteínas quinasas.
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
IN2014MN02598A (de)
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
RS54526B1 (en) USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
MY172422A (en) Pyrazole compound and pharmaceutical use thereof
GB201209587D0 (en) Therapeutic compounds
PH12015502429A1 (en) Dicarboxylic acid compound
MX2013005819A (es) Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion.
MX2014015345A (es) Inhibidores piranopiridona de tanquirasa.
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
CY1117011T1 (el) Παραγωγα αζολιου
MY163185A (en) 2-methoxy-pyridin-4-yl derivatives
MX2015002705A (es) Compuestos de piridinona para usarse en terapia fotodinamica.
IN2014CN04922A (de)
MY173812A (en) 2-pyridone compound